Resmed Stock Price, News & Analysis

ResMed (NYSE: RMD) announced that Rob Douglas, the president and COO, will present at the Oppenheimer 33rd Annual Healthcare Conference on March 13, 2023, at approximately 11:20 a.m. EDT. The presentation will be accessible via a webcast, and interested parties can find more information and access the live stream on ResMed's investor relations website. A replay will be available approximately 24 hours after the event and can be accessed for 90 days. ResMed specializes in innovative solutions for chronic diseases, enhancing care with digital health technologies and cloud-connected medical devices across over 140 countries.

ResMed (NYSE: RMD) has appointed Mick Farrell as the new chair of the board, effective January 25, 2023. Farrell, who has been CEO since March 2013, succeeds Peter Farrell, who will transition to chair emeritus but remain on the board. Under Mick's leadership, ResMed's market capitalization surged from $6 billion to over $30 billion, achieving a total shareholder return of 507% over the past decade. The board believes combining the CEO and chair roles will enhance efficiency and align with practices of many S&P 500 peers. The company aims to positively impact 250 million lives by 2025.

ResMed reported a 16% year-over-year revenue growth for Q2 2023, totaling $1,033.7 million. This growth was driven by strong demand for sleep and respiratory care devices and an increase of 20% on a constant currency basis. Operating income also increased by 13%, while non-GAAP operating profit rose by 14%. The company achieved a diluted EPS of $1.53 and a non-GAAP diluted EPS of $1.66, reflecting a 13% increase from the previous year. ResMed completed the acquisition of MEDIFOX DAN, enhancing its Software-as-a-Service (SaaS) offerings in Europe. A quarterly cash dividend of $0.44 per share was declared, payable on March 16, 2023.

ResMed (NYSE: RMD) will release its financial and operational results for Q2 FY2023 on January 26, 2023, after NYSE closure. A webcast will follow to discuss these results, starting at 1:30 p.m. PDT (4:30 p.m. EDT). The event will also cover additional forward-looking and material information. Investors can access the webcast at ResMed's investor website. A replay will be available two hours post-webcast, along with a phone replay until February 9, 2023.

ResMed (NYSE: RMD) announced that CEO Mick Farrell will present at the 41st Annual J.P. Morgan Healthcare Conference on January 9, 2023, at 1:30 p.m. PST in San Francisco. The company is known for its innovative solutions aimed at treating chronic diseases like sleep apnea and COPD, enhancing patients' quality of life through digital health technologies. Investors can access the live audio-only webcast and a replay will be available post-event for 30 days. ResMed operates in over 140 countries, focusing on out-of-hospital support systems.

ResMed has acquired MEDIFOX DAN, a leading German software solutions provider, for €958.6 million ($997.5 million). This strategic acquisition marks ResMed's first expansion of its SaaS business into Germany, the second largest healthcare market globally. MEDIFOX DAN will enhance ResMed's portfolio with outpatient therapy service offerings, and its operations will integrate within ResMed's SaaS segment. The acquisition is expected to be accretive to non-GAAP diluted earnings per share, while ResMed plans to retain all MEDIFOX DAN employees and maintain its current brand.

ResMed (NYSE: RMD) reported a 5% year-over-year revenue growth for Q1 2023, totaling $950.3 million, with a 9% increase on a constant currency basis. Operating profit rose 5%, while non-GAAP operating profit increased 4%. Diluted earnings per share increased to $1.43, with a non-GAAP EPS of $1.51. The company noted strong sales in the Americas and expanding gross margins despite increased SG&A expenses. Additionally, ResMed announced the acquisition of mementor and unveiled plans to double its R&D workforce in Ireland.

ResMed (NYSE: RMD) will release its financial and operational results for Q1 FY 2023 on October 27, 2022, post-market hours. A webcast will follow to discuss these results and any additional forward-looking information. The earnings call will be accessible to international audiences, with a replay available shortly after. ResMed focuses on innovative healthcare solutions that enhance the quality of life for individuals with chronic diseases, aiming to lower costs for consumers and healthcare systems globally.